Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroneticsSTIM -0.84%59 3-Year EBITDA Growth Rate is 29.00% as of Jun. 2026, which is 16% above its 10-year median of 25.10. GuruFocus rates STIM with a GF Score™ of 59/100 and a GF Value™ of $1.78 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Neuronetics ranks better than 76.23% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Neuronetics was 89.40% per year. The lowest was -1.70% per year. And the median was 25.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Neuronetics 3-Year EBITDA Growth Rate Related Terms
STIM vs MXCT, CVRX, RCEL: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Neuronetics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuronetics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Neuronetics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.00% mean?
Neuronetics (STIM) has a 3-Year EBITDA Growth Rate of 29.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Neuronetics and its competitors. This is 16% above median its historical median of 25.10. According to the industry distribution chart, Neuronetics ranks #164 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 23.8%.
Is Neuronetics' 3-Year EBITDA Growth Rate too high?
Neuronetics' current 3-Year EBITDA Growth Rate of 29.00% is 16% above median its 10-year median of 25.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Neuronetics' value of 29.00% is 258% above this industry median. Based on the distribution chart, Neuronetics ranks #164 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Neuronetics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' 3-Year EBITDA Growth Rate compare to MXCT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, Neuronetics ranks #164 out of 690 companies for 3-Year EBITDA Growth Rate. This places Neuronetics in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Neuronetics' value of 29.00% is 258% above this benchmark. While the company's 10-year median is 25.10 vs. the industry median of 8.10, Neuronetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuronetics's current 3-Year EBITDA Growth Rate of 29.00% is 258% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Neuronetics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuronetics's current 3-Year EBITDA Growth Rate is 29.00%, which is 16% above median its own 10-year median of 25.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (STIM) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.78, compared to a current price of $2.97 — trading 66.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 29.00%, which is 16% above median its 10-year median of 25.10 and 258% above the Medical Devices & Instruments industry median of 8.10. Neuronetics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Neuronetics (STIM), the current 3-Year EBITDA Growth Rate is 29.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuronetics (STIM) Overvalued in 2026?
Based on GuruFocus' analysis, Neuronetics stock appears to be overvalued.
The current stock price of $2.97 is trading 66.9% above its estimated GF Value™ of $1.78.
GuruFocus considers Neuronetics to be Significantly Overvalued.
Key valuation signals for STIM:
3-Year EBITDA Growth Rate: 29.00% (16% above median its 10-year median of 25.10)
GF Value™: $1.78 vs. price of $2.97 (66.9% above fair value)
Industry Position: 258% above the Medical Devices & Instruments median (#164 of 690)
No single metric tells the full story. See the STIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
59GF Score
Get the complete analysis for STIM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STIM has been successfully added to your 
